Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before the bell. Here’s what to expect. Moderna missed analysts’ revenue expectations by 8.4% last quarter, reporting ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

Moderna’s LP.8.1-adapted COVID-19 vaccine has been recommended by the European Medicines Agency (EMA)’s human medicines ...

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the COVID-19 vaccine Spikevax®, targeting the ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

If you're confident that its current trials will prove successful, then this is one to buy and sit on. One word of caution ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Moderna has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...